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Background: Impaired coronary microcirculation is associated with a poor prognosis in patients with type 2 diabetes.
In the absence of stenosis of major coronary arteries, coronary flow reserve (CFR) reflects coronary microcirculation.
Studies have shown beneficial effects of glucagon-like peptide-1 (GLP-1) on the cardiovascular system. The aim of the
study was to explore the short-term effect of GLP-1 treatment on coronary microcirculation estimated by CFR in
patients with type 2 diabetes.
Methods: Patients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1
analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with
a 2 weeks wash-out period. The effect of liraglutide on coronary microcirculation was evaluated using non-invasive
trans-thoracic Doppler-flow echocardiography during dipyridamole induced stress. Peripheral microvascular endothelial
function was assessed by Endo-PAT2000®. Interventions were compared by two-sample t-test after ensuring no carry
over effect.
Results: A total of 24 patients were included. Twenty patients completed the study (15 male; mean age 57 ± 9; mean
BMI 33.1 ± 4.4, mean baseline CFR 2.35 ± 0.45). There was a small increase in CFR following liraglutide treatment
(change 0.18, CI95% [-0.01; 0.36], p = 0.06) but no difference in effect in comparison with no treatment (difference
between treatment allocation 0.16, CI95% [-0.08; 0.40], p = 0.18). Liraglutide significantly reduced glycated haemoglobin
(HbA1c) (-10.1 mmol/mol CI95% [-13.9; -6.4], p = 0.01), systolic blood pressure (-10 mmHg CI95% [-17; -3], p = 0.01) and
weight (-1.9 kg CI95% [-3.6; -0.2], p = 0.03) compared to no treatment. There was no effect on peripheral microvascular
endothelial function after either intervention.
Conclusions: In this short-term treatment study, 10 weeks of liraglutide treatment had no significant effect on neither
coronary nor peripheral microvascular function in patients with type 2 diabetes. Further long-term studies, preferably in
patients with more impaired microvascular function and using a higher dosage of GLP-1 analogues, are needed to
confirm these findings.
Trial registration: ClinicalTrials.gov: NCT01931982.
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Patients with type 2 diabetes often suffer from both
macro- and microvascular disease with cardiovascular dis-
ease being the most important contributor to mortality.
Myocardial microvascular dysfunction is caused by re-
duced vasodilator reserve of the small coronary arteries.
In case of dysfunctioning microvessels, blood flow in the
larger coronary vessels does not increase sufficiently to
meet oxygen demand. In the absence of stenosis of major
coronary arteries, coronary microcirculation is reflected
by the coronary flow reserve (CFR). CFR is reduced in pa-
tients with hypertension, obesity and diabetes [1,2]. Re-
duced CFR has been proven a strong predictor of poor
prognosis in patients with suspected coronary artery
disease (CAD) [3-5]. Recently, studies have shown CFR
to provide independent prognostic information on pa-
tients with type 2 diabetes and no history of CAD. Pa-
tients with a low CFR had a significantly higher event
rate of cardiovascular endpoints compared to patients
with higher CFR [6,7].
Glucagon-like-peptid-1 (GLP-1) analogues are a group
of drugs used in the treatment of type 2 diabetes. GLP-1
is an endogenous incretin hormone with pleiotropic
metabolic effects [8]. GLP-1 analogues stimulate insulin
release in a glucose dependent manner and reduce glu-
cagon levels and appetite leading to reduced glycaemia
and weight loss. Data from both animal- and clinical
studies suggest beneficial effects of GLP-1 on the cardio-
vascular system. GLP-1 receptors are found throughout
the gastrointestinal tract as well as in cardiomyocytes,
endothelium and the sinoatrial node [9,10]. GLP-1 has
been shown to enhance glucose uptake in the myo-
cardium of isolated rat hearts and in dog myocardium
[11,12]. Other potential beneficial effects of GLP-1
shown in animal studies include increased vasodilatation
and coronary flow and activation of cardio protective
pathways in murine heart models [13,14]. These changes
were associated with improved survival and reduced in-
farct size after experimentally induced myocardial infarc-
tion [14].
In humans, Nikolaidis et al. [15] were the first to show
an improvement of left ventricular ejection fraction
(LVEF) following infusion of GLP-1 in patients with
acute myocardial infarction. Other studies have found
improvement of LVEF in patients with CAD during a
dobutamine stress test [16] and in patients with chronic
heart failure [17]. The mechanism behind this improve-
ment is unclear. However, one study has found an in-
crease in global myocardial blood flow in eight patients
with type 2 diabetes following 6 hours of GLP-1 ana-
logue infusion [18]. Similarly, a study by Subaran et al.
has shown GLP-1 infusions recruit cardiac muscle mi-
crovasculature and increase myocardial blood flow in
healthy humans [19]. Recently, animal studies havefound GLP-1 protects cardiac microvessels against oxi-
dative stress and apoptosis in diabetic rats [20] and pre-
serves microvascular myocardial function estimated by
CFR in a swine model after experimentally induced car-
diac arrest [21]. Therefore, we hypothesize that GLP-1
treatment can improve myocardial microvascular func-
tion assessed by CFR in patients with type 2 diabetes.
Methods
The study was a randomized single-blinded cross-over
trial with a 1:1 allocation ratio. This design was chosen to
allow each patient to serve as his or her own control.
Figure 1 shows the study flow chart. Participants were
randomized to receive the same treatment in different se-
quences either 1) 10 weeks of GLP-1 analogue followed by
a 2 weeks wash-out period followed by 10 weeks of usual
anti-diabetic therapy only (sequence 1) or 2) 10 weeks of
usual anti-diabetic therapy only followed by 10 weeks of
GLP-1 analogue (sequence 2). Hence, patients randomized
to sequence 1 participated in the study for 22 weeks and
patients randomized to sequence 2 participated for 20
weeks. All endpoints were evaluated at baseline, after 10,
12 and 22 weeks for sequence 1 and at baseline and after
10 and 20 weeks for sequence 2. The study was approved
by The Danish Research Ethics Committee (H-3-2012-177),
The Danish Health and Medicines Authorities (2012-
005013-38) and has been continuously monitored by the
GCP-unit at Bispebjerg University Hospital, Denmark.
The study is registered at www.clinicaltrials.gov, with the
ClinicalTrials.gov Identifier: NCT01931982.
Inclusion criteria were: type 2 diabetes on monotherapy
with metformin or sulfonylurea (SU) or a combination, age
25-75 years, BMI > 25 kg/m2, HbA1c 42-86 mmol/mol,
ability to speak and understand Danish or English and the
mental ability to follow and understand the study, as
assessed by the investigator.
Main exclusion criteria were: current treatment with
insulin, DPP-4 inhibitor or GLP-1 analogue, history of
cardiovascular disease including documented significant
stenosis of the left anterior descending artery (LAD),
allergy towards the test drug liraglutide (Victoza®), tool
medicine dipyridamole or rescue medicine teophylline,
chronic or previous acute pancreatitis, inflammatory
bowel disease or pregnancy. Patients with severe co-
morbidity or limited life expectancy were also excluded
from the study. If dipyridamole stress test at baseline
showed signs of significant ischemia the patient was ex-
cluded from the study. Patients were recruited from
three different outpatient clinics in the capital region of
Denmark. All data collection and analysis was carried
out at Bispebjerg University Hospital. After screening for
eligibility, written informed consent was collected for all
participants. Inclusion was consecutive until 20 patients
had completed the study.
Wash out period
2 weeks – Sequence 1
No treatment No treatment











Figure 1 Study flow chart.
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taneous treatment with the GLP-1 analogue liraglutide
(Victoza®) 6 mg/ml. Liraglutide was add-on to usual
treatment (metformin, SU or metformin and SU) unless
blood glucose levels indicated discontinuation of SU due
to risk of hypoglycaemia. Patients were started on an
initial dose of 0.6 mg once daily for two weeks to assess
tolerability of the drug and to minimize potential gastro-
intestinal side-effects. After two weeks the dose was
increased to 1.2 mg s.c once daily. The withdrawal cri-
teria were: a) Patient’s wish to discontinue, b) Sustained
gastrointestinal side-effects making the patients unable
to increase liraglutide to full dose, and c) Repeated non-
adherence to taking liraglutide as assessed by the in-
vestigator. Compliance was evaluated after one and two
weeks of treatment by phone interviews. At the second
compliance check, patients were also instructed to
increase dosage to the full dose. Empty pens were col-
lected from each patient after completion of the inter-
vention to further assess compliance.
Primary endpoint was CFR assessed by a non-invasive
trans-thoracic Doppler flow echocardiography. Secondary
endpoint was peripheral endothelial function, assessed by
Endo-PAT2000®. Additional endpoints were weight, waist
circumference, blood pressure, heart rate, HbA1c and
fasting C-peptide, plasma glucose and serum insulin
for the calculation of Homeostatic Model Assessment
(HOMA) index.
Calculation of sample size was based on the assump-
tion that an improvement of 0.3 in CFR (i.e. approx. 15%
of an expected mean CFR of 2) was regarded as clinically
relevant. With an expected standard deviation within
subject measurement of CFR of 0.3, alpha of 0.05 and
statistical power of 0.9, we needed to study 13 patients
in a cross-over design. However, considering the risk of
drop-out we chose to include 20 patients.
Coronary flow reserve
CFR was assessed non-invasively by trans-thoracic Doppler
flow echocardiography. All patients were instructed to ab-
stain from food and drinks containing xanthine (coffee,tea, cola, chocolate, and banana) for 24 hours before the
examination. Use of nitroglycerin and antihypertensive
drugs were also discontinued for 24 hours. With the pa-
tient in the left supine position, the LAD was identified in
the best possible view. Whether the location was at the
proximal, mid-distal or distal part of the artery depended
on patient variability such as respiration pattern and de-
gree of obesity. After locating the artery the ultrasound
probe was rotated and tilted to obtain the best possible
Doppler signal. Coronary flow velocity was measured at a
minimum of 3 cardiac circles at rest and during peak
pharmacological stress induced by dipyridamole infusion
(0.84 mg/kg) for 6 minutes. Patients were monitored with
blood pressure and 3-lead electrocardiogram before and
during the infusion. Care was taken to maintain the posi-
tion and angle of the probe. Immediately after the exami-
nation, peak velocities at stress and at rest were measured
and CFR was calculated as the ratio of flow during stress
to during rest, see Figure 2. After the examination, the pa-
tient was observed for 30 minutes before leaving the site.
The investigator was blinded to which group the patient
belonged to throughout the study.
Endothelial function
Peripheral microvascular endothelial function was as-
sessed with the commercially available Endo-PAT2000®
(Itamar Medical, Caesarea, Israel). This is a non-invasive,
observer-independent technique that offers automatic
data-analysis [22]. Endo-PAT2000® uses peripheral arterial
tonometry (PAT) technology to measure volume changes
in the fingertip before and after occlusion. Measurements
from the contra-lateral arm are used to control for non-
endothelial dependent changes in vascular tone. The auto-
matically calculated ratio (reactive hyperaemia index = RHI)
provides an index for endothelial function.
Blood pressure and heart rate were recorded three
times with 2 minutes interval before the examination.
The mean of the last two recordings served as baseline
blood pressure and heart rate. The examination was per-
formed in a fasting state in a quiet dark room with room
temperature 21-24°C using bilateral digital probes. A
Figure 2 Measuring CFR by Doppler flow echocardiography. Left anterior descending artery (LAD) flow during rest (A) and LAD flow during
dipyridamole induced stress (B).
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minutes followed by 5 minutes of cuff occlusion of the
non-dominant arm. Occlusion was aimed at a minimum
of 60 mmHg above the baseline systolic blood pressure
to ensure complete occlusion. Cuff was released and
digital flow was recorded in 5 minutes and the relative
increase in flow adjusted for the non-tested arm was
automatically calculated (RHI).
During the examination, several unintended actions
can interrupt the PAT signal. This includes noisy signal,
sudden movement of one arm if the patient falls asleep
and incomplete occlusion of the cuff (the pressure falls
under 60 mmHg above the systolic pressure at baseline).
The machine will then add a warning signal to the auto-
matically calculated RHI index.Additional secondary outcomes
Blood samples were taken in a fasting state. Samples for
HbA1c were analysed using standard methods. Samples
for plasma glucose, serum insulin and serum C-peptide
were taken twice with an interval of 15 minutes and im-
mediately put on ice. An average of the two samples was
used for later analysis. Plasma glucose was measured
using YSI 2300 STAT Plus Glucose Analyzer (YSI Life
Sciences, Ohio, USA). Serum insulin and C-peptide were
measured using AutoDELFIA® immunoassay systems
(PerkinElmer, Massachusetts, USA). HOMA IR index
was calculated as (fasting insulin (μU/ml) × fasting glucose
(mmol/L))/22.5. Blood pressure recordings were measured
as stated above in connection with the EndoPAT2000®
examination. Subjects were defined as hypertensive if they
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was above 140/90 mmHg. Dyslipidaemia was defined as
triglyceride or cholesterol levels above normal range or
patients on lipid lowering agent.
Randomization procedure
Randomization concerning sequence of intervention was
supervised by the regional GCP unit. The patient was
asked to draw a number from a box containing 20 num-
bers. Numbers 1-10 represented sequence 1 and num-
bers 11-20 represented sequence 2. If a patient withdrew
from the study, making inclusion of another patient ne-
cessary, the corresponding number was put back in the
box. After randomization the patient was identified by a
number and followed the study according to the se-
quence he or she was assigned to. A research assistant
performed the randomization procedure and allocation.
The investigators who performed the primary outcome
examination by echocardiography had no knowledge of
which sequence the patient belonged to.
Statistical analyses
Carry over effects were measured using the pkcross com-
mand in Stata 13.1 for cross-over design experiment. The
command calculates carry over, period, sequence and
treatment effect. Using different parameterizations, the
treatment effect can be measured in assumption of no
carry over, period or sequence effect. Data was analyzed as
two-sample t-test comparing changes within and between
liraglutide treatment and no treatment allocations after
ensuring there was no carry over, sequence or period
effect. Paired two-sample t-test was used for within alloca-
tion comparisons whereas unpaired two-sample t-test was
used for between treatment allocation comparisons. Con-
tinuous variables are expressed as mean ± SD, categorical
variables as frequency and percentage. A p-value of ≤ 0.05
was considered statistically significant. All analyses were
performed in Stata 13.1 (Stata Statistical Software: Release
13. College Station, Texas, USA).
Results
Study population
We assessed 621 patients who were followed for type 2
diabetes in outpatient clinics for eligibility (Figure 3). 213
patients were excluded due to co-morbidity, primarily pre-
vious CAD (37%, including AMI, PCI and CABG), re-
duced renal function (13%) and gastrointestinal disease
(12%, including inflammatory bowel disease, previous
pancreatitis and gastric bypass). Eligible patients (n = 81)
were invited to participate. Of these, 56 declined. The
main reason for reluctance to participating in the study
was the concern for potential side-effects to the test
drug liraglutide (Victoza®). Twenty-four patients were
randomized, 14 to sequence 1 and 10 to sequence 2.During the follow up period from 15.05.2013 to
15.04.2014 one patient was lost to follow up and three
patients withdrew due to sustained gastrointestinal side-
effects to the liraglutide treatment in sequence 1. There
were no withdrawals in sequence 2. Liraglutide was gen-
erally well tolerated and side-effects were transient with
duration of approximately two weeks. Background the-
rapy needed readjustment during liraglutide treatment
in 3 out of the 4 patients receiving both metformin and
SU. In one case, SU dosage was halved and in two cases
SU was paused during liraglutide treatment due to
HbA1c levels indicating risk of hypoglycaemia. No inci-
dents of hypoglycaemia were observed. Three patients
developed angina-like symptoms and were referred to
either stress echocardiography or CT angiography to
rule out obstructive CAD. None of these tests came out
positive and the patients continued the study protocol.
In both sequences, a total of 10 patients received the full
10 weeks liraglutide treatment.
Table 1 describes baseline characteristics and echocardio-
graphic data of the two sequences and the total study popu-
lation. Participants were predominantly male (75%), with a
mean age of 57 ± 9 years, were obese (BMI 33.1 ± 4.4) and
had a mean HbA1c of 52.8 ± 8.2 mmol/mol. There were a
high percentage of known cardiac risk factors such as
hypertension (80%) and dyslipidaemia (95%) in the study
population. Echocardiographic data showed a LVEF within
the normal range (mean 54.6 ± 5.8). CFR ranged from 1.69
to 3.11 (mean 2.35 ± 0.45).
Coronary flow reserve
In two of the 70 echocardiographies performed the in-
vestigator was unable to identify LAD in the same seg-
ment compared to previous examinations for the same
patient and recordings obtained at these two exami-
nations were of poor quality. Thus, 2 patients were ex-
cluded from CFR assessment in sequence 1 because of
unreliable comparability with previous examinations.
Analysis of CFR was then carried out for 8 patients in
sequence 1 and 10 patients in sequence 2. Adverse reac-
tions to dipyridamole included flushing, headache, short-
ness of breath and increased heart rate, but generally
dipyridamole was well tolerated. No cardiac arrhythmias
were observed during the dipyridamole infusions.
Table 2 shows changes in CFR values before and after no
treatment and liraglutide treatment allocation. There was
no significant change in CFR during no treatment (before
2.45 ± 0.41; after 2.47 ± 0.42, p = 0.82). Liraglutide treat-
ment caused a small increase in CFR, which was of bor-
derline significance (before 2.25 ± 0.31; after 2.43 ± 0.39,
p = 0.06).
Table 3 shows the difference between changes in CFR
in the no treatment and the liraglutide treatment alloca-
tion. The difference between treatment allocations was
Figure 3 Participant flow chart.
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p = 0.18).
Peripheral endothelial function
Analyses were carried out for all 20 patients. There were
no changes in RHI in the no treatment allocation (before
1.84 ± 0.41; after 1.87 ± 0.35, p = 0.70) or the liraglutide
treatment allocation (before 1.89 ± 0.47; after 2.00 ± 0.40,
p = 0.31) and no between treatment allocation difference
(0.09, CI95% [-0.17; 0.36], p = 0.49) (Table 3). Further-
more, there was no effect on arterial stiffness, measured
by augmentation index (AI), following liraglutide treat-
ment compared to no treatment (0.20, CI95% [-5.7; 6.1],
p = 0.95). Results were similar when examinations with a
warning signal were removed (n = 6) (difference between
changes in RHI in the two treatment allocations (0.19,
CI95% [-0.07; 0.45], p = 0.14).
Additional secondary outcomes
Liraglutide treatment was associated with a signifi-
cant decrease in HbA1c compared with no treatment
(-10.1 mmol/mol, CI95% [-13.9; -6.4], p = 0.01), a de-
crease in fasting plasma glucose (-2.13 mmol/L, CI95%[-3.24; -1.03], p < 0.001), a moderate weight loss (-1.9 kg,
CI95% [-3.6; -0.2], p = 0.03) and a reduction in systolic
blood pressure (-10 mmHg, CI95% [-17; -3], p = 0.01).
Carry over effect was found for one variable, HbA1c, but
taking this into the parameterization in the pkcross
command, the effect of liraglutide remained significant
(p = 0.01 versus p = <0.001). Please see Additional file 1
for carry over, period and sequence effect for all outcomes.
There was no effect of liraglutide treatment on diastolic
blood pressure (-2 mmHg, CI95% [-7; 3], p = 0.35), heart
rate (0.05 bpm, CI95% [-6; 6], p = 0.97) or waist circum-
ference (1 cm, CI95% [-2; 2], p = 0.96) compared with no
treatment. Additionally, liraglutide had no effect on serum
insulin (-6 μU/ml, CI95% [-34; 21], p = 0.65), serum
C-peptide (31 pmol/L, CI95% [-150; 212], p = 0.73) or
HOMA index (-1.6, CI95% [-3.7; 0.5], p = 0.13).
Discussion
In the present study, we compared the changes in
coronary flow reserve after 10 weeks of treatment with
1.2 mg liraglutide daily versus no treatment in patients
with type 2 diabetes. Although liraglutide was associated
with weight loss, lower systolic blood pressure and
Table 1 Baseline characteristics and echocardiographic data of study subjects
Variables Sequence 1 (N = 10) Sequence 2 (N = 10) p-value* Total study population (N = 20)
Age (years) 57 ± (9) 56 ± (9) 0.87 57 ± (9)
Male gender 7 (70%) 8 (80%) 0.63 15 (75%)
Duration type 2 diabetes (years) 4 ± (3) 5 ± (3) 0.35 4 ± (3)
BMI (kg/m2) 34.8 ± (4.1) 31.4 ± (4.1) 0.08 33.1 ± (4.4)
Waist circumference (cm) 119 ± (11) 111 ± (8) 0.08 115 ± (10)
HbA1c (mmol/mol) 51.1 ± (4.8) 54.5 ± (10.6) 0.37 52.8 ± (8.2)
eGFR (ml/min/1.73 m2) 89 ± (3) 87 ± (6) 0.37 88.2 ± (4.8)
Haemoglobin (mmol/L) 9.0 ± (0.5) 8.9 ± (0.7) 0.75 8.9 ± (0.6)
Hypertension 7 (70%) 9 (90%) 0.29 16 (80%)
Dyslipidaemia 10 (100%) 9 (90%) 0.33 19 (95%)
Micro albuminuria** 0 (0%) 3 (30%) 0.07 3 (15%)
Diabetes treatment:
Biguanide 10 (100%) 10 (100%) 1.00 20 (100%)
Sulfonylurea 1 (10%) 3 (30%) 0.29 4 (20%)
Other treatment:
Statin 8 (80%) 7 (70%) 0.63 15 (75%)
ACE inhibitor 2 (20%) 4 (40%) 0.36 6 (30%)
Beta blocker 0 (0%) 3 (30%) 0.07 3 (15%)
LVEF (%) 52.8 ± (5.4) 56.3 ± (6.0) 0.17 54.6 ± (5.8)
Peak diastolic flow at rest (cm/sec) 0.26 ± (0.06) 0.26 ± (0.06) 0.94 0.26 ± (0.06)
Peak diastolic flow during stress (cm/sec) 0.58 ± (0.12) 0.64 ± (0.17) 0.35 0.61 ± (0.14)
CFR 2.26 ± (0.48) 2.44 ± (0.44) 0.39 2.35 ± (0.45)
Data are presented as mean (± SD) or n (%). *P-value for difference in variables between sequence 1 and sequence 2. Two-sided T-tests were used. **Micro albuminuria
was defined as (U-Albumin/U-Creatinine Ratio > 30). Abbreviations: HbA1c glycated haemoglobin, eGFR estimated glomerular filtration rate, LVEF Left ventricular ejection
fraction, CFR coronary flow reserve.










CFR 2.45 (0.41) 2.47 (0.42) 0.82 2.25 (0.31) 2.43 (0.39) 0.06
RHI 1.84 (0.41) 1.87 (0.35) 0.70 1.89 (0.47) 2.00 (0.40) 0.31
AI 11.1 (15.4) 9.7 (16.5) 0.49 10.6 (17.9) 9.4 (14.0) 0.58
HbA1c (mmol/mol) 49.8 (9.3) 50.8 (8.9) 0.52 52.1 (7.2) 42.9 (4.0) <0.0001
Weight (kg) 100.6 (10.1) 100.5 (10.4) 0.89 100.9 (10.8) 98.8 (11.7) <0.01
Systolic BP (mmHg) 140 (12) 144 (14) 0.10 143 (14) 137 (12) 0.02
Diastolic BP (mmHg) 80 (6) 81 (9) 0.42 81 (7) 80 (6) 0.62
Fasting glucose (mmol/L) 7.74 (1.54) 8.26 (2.18) 0.23 8.44 (1.90) 6.83 (1.16) <0.001
Insulin (pmol/L) 85 (46) 82 (41) 0.71 87 (45) 77 (41) 0.37
C-peptide (pmol/L) 969 (362) 990 (337) 0.74 1046 (374) 1098 (401) 0.41
HOMA index 4.9 (2.8) 4.9 (2.6) 0.93 5.5 (3.4) 4.0 (2.4) 0.06
Data are presented as mean (SD). *P-value for the difference between values before versus after no treatment or liraglutide treatment, respectively. Two-sided
T-tests were used under the assumption of no carry over effect. Abbreviations: CFR coronary flow reserve, RHI reactive hyperaemia index, AI augmentation index,
HbA1c glycated haemoglobin, BP blood pressure, HOMA Homeostatic Model Assessment.
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CFR 0.02 (0.32) 0.18 (0.38) 0.16 [-0.08; 0.40] 0.18
RHI 0.03 (0.30) 0.12 (0.51) 0.09 [-0.17; 0.36] 0.49
AI -1.4 (8.9) -1.2 (9.6) 0.20 [-5.7; 6.1] 0.95
HbA1c (mmol/mol) 0.9 (6.3) -9.2 (5.1) -10.1 [-13.9; -6.4] 0.01
Weight (Kg) -0.1 (2.5) - 2.0 (2.8) -1.9 [-3.6; -0.2] 0.03
Waist circumference (cm) -1 (4) -1 (2) 1 [-2; 2] 0.96
Systolic BP (mmHg) 5 (12) -5 (9) -10 [-17; -3] 0.01
Diastolic BP (mmHg) 1 (7) -1 (8) -2 [-7; 3] 0.35
Heart rate (bpm) 4 (10) 4 (9) 0.05 [-6; 6] 0.97
Fasting glucose (mmol/L) 0.52 (1.85) -1.61 (1.54) -2.13 [-3.24; -1.03] <0.001
Insulin (μU/ml) -3 (39) -10 (45) -6 [-34; 21] 0.65
C-peptide (pmol/L) 21 (280) 52 (279) 31 [-150; 212] 0.73
HOMA index 0.1 (3.6) -1.5 (3.2) -1.6 [-3.7; 0.5] 0.13
Data are presented as mean (SD). *P-value for the difference between changes in treatment allocations: liraglutide treatment versus no treatment. Two-sided
t-tests were used under the assumption of no carry over effect. Abbreviations: CFR coronary flow reserve, RHI reactive hyperaemia index, AI augmentation index,
HbA1c glycated haemoglobin, BP blood pressure, HOMA Homeostatic Model Assessment.
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insignificant improvement in CFR.
To our knowledge, apart from one short-acting GLP-1
infusion intervention study in healthy humans [19] no
clinical trial has evaluated the effect of GLP-1 on coro-
nary microcirculation. Few animal studies, including a
rat and two swine models, have addressed coronary
microcirculation following GLP-1 treatment. These stu-
dies found GLP-1 had a protective anti-oxidative effect on
coronary microvessels [20,21,23]. Furthermore, Dokken
et al. found GLP-1 preserved, but did not improve,
myocardial microvascular function estimated by CFR in
an acute setting of swine subjected to experimentally in-
duced cardiac arrest. These effects were not associated
with an improvement in survival or LVEF [23]. In the
present study, the population consists of patients with
type 2 diabetes and no history of CAD, myocardial ische-
mia or heart failure. In the previous clinical studies sho-
wing GLP-1 had a positive effect on the cardiovascular
system the study populations suffered from acute myocar-
dial infarction, CAD or chronic heart failure [15-17]. The
positive effects found by others might be due to improved
myocardial glucose uptake under myocardial ischaemic
conditions [24] rather than direct effects on the cardiovas-
cular system.
We did find a trend towards an increase in CFR in the
liraglutide treatment allocation alone, although this in-
crease was modest and only of borderline significance. It
is possible that a short-term treatment study is in-
adequate to induce the structural changes needed for an
improvement in the coronary microcirculation. More-
over, we cannot rule out that 1.8 mg or 3 mg (recently
approved for weight loss) could have improved the effectof liraglutide on CFR further. However, we chose 1.2 mg
as this dose is well accepted for glycaemic control and to
minimize the risk of gastrointestinal side-effects.
The enrolled patients had a better coronary micro-
vascular function than expected which may have limited
the treatment effect (i.e., a ‘ceiling effect’). Furthermore,
coronary microvascular dysfunction is known to be
more common in women than in men [25] and some
studies have shown higher incidents of microvascular
dysfunction in African Americans compared to white
Americans [26]. The current study population consists
of Danish white Caucasians with a greater proportion of
men (75%). GLP 1 treatment in women or patients with
documented microvascular angina might have a different
outcome.
Nevertheless, during liraglutide treatment CFR im-
proved by 0.18 from a baseline value of 2.35 or equiva-
lent of 8% and the upper limit of the confidence interval
was 0.36 or 15%. Therefore, we are not likely to overlook
clinically relevant improvements in this study population
and in particular not improvements caused by direct
effects of liraglutide. Diabetes, hypertension and over-
weight are strongly related to impaired CFR [1,2] and it
is likely that any modest improvement in CFR is caused
by the significant improvement in glycemic regulation,
systolic blood pressure and moderate weight loss found
in this study.
Our findings of liraglutide improving glycemic regulation,
reducing systolic blood pressure and body weight are in
concordance with several others studies [27-29]. On-going
long-term clinical trials will clarify the cardiovascular effects
of GLP-1 analogues [30]. Interestingly, the first studies de-
signed to evaluate the long-term effects of DDP-4 inhibitors
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We found no effect of liraglutide treatment on peri-
pheral endothelial function assessed by Endo-PAT2000®.
Endo-PAT2000® has been validated against invasive mea-
surements of endothelial function with good results [33]
and has been linked to several traditional cardiovascular
risk factors [22]. Furthermore, one study has evaluated
its implication for clinical trials, and concluded that
Endo-PAT2000® can detect treatment effects in relative
small sample sizes (n = 15-30) [34]. However, the me-
thod differs from the ‘gold standard’ of assessing periphe-
ral endothelial function by flow-mediated vasodilation and
the validity of the RHI index derived as a measure of
endothelial function has recently been questioned [35].
Our findings are in line with other studies that found no
effect of GLP-1 analogues on peripheral endothelial func-
tion estimated by flow-mediated dilation in patients with
type 2 diabetes and estimated by RHI in a pre-diabetic
population [36,37]. In contrast, A. Gnasso and his group
did find an improvement in endothelial function following
GLP-1 analogue treatment [38] although this study was
observational. A recent study by Rizzo et al. [39] found
liraglutide significantly decreased carotid intima-media
thickness, a marker of subclinical atherosclerosis, but
whether this translates to positive influence on the peri-
pheral microvascular endothelial function is unclear.
Another clinical randomized trial found improvement of
several markers of vascular function but failed to show an
effect of GLP-1 on arterial stiffness (AI) which is in
accordance with our findings [40]. Also, recent evidence
suggests potential harmful effects of DDP4-inhibitors on
peripheral endothelial function [41]. In summary, the
current evidence on the effects of GLP-1 on peripheral
endothelial function is conflicting and based on small
studies [42]. Our findings contribute to a negative position
towards a GLP-1 potential for improving peripheral endo-
thelial function in patients with type 2 diabetes.
Strengths and limitations
The applied technique of measuring CFR non-invasively
with Doppler flow echocardiography is technically deman-
ding. The technique is used routinely in our echolab and
has been validated in previous studies against invasive mea-
surements [43,44] and PET [45] with good agreement. Al-
ternative methods for assessing coronary microcirculation
are invasive by thermo dilution or intracoronary Doppler
flow assessment or by PET CT. PET CT has less availa-
bility, is associated with radiation and there is no evidence
to suggest that PET CT is a more sensitive measure
than transthoracic Doppler flow echocardiography. Cardiac
Magnetic Resonance Imaging (MRI) is a promising method
that has not yet been standardized for quantitative assess-
ment of coronary microvascular function [46]. We chose touse transthoracic Doppler echocardiography because it is
non-invasive, reproducible and does not expose the patients
repeatedly to radiation.
We found the standard deviation of the difference bet-
ween two CFR values for the same patient to be higher
than expected (0.38 versus 0.30). Although we did include
a greater number of patients than the statistical power esti-
mation required, the actual higher SD increases the risk of
a type 2 error in this study. However, as discussed above,
we are not likely to overlook clinically relevant improve-
ments and in particular no improvements caused by direct
effects of liraglutide.
The population consisted of patients with type 2 diabetes
without symptoms or history of CAD by inclusion in the
study. Three patients developed angina-like symptoms but
had no signs of significant coronary lesions in additional
examinations. We cannot rule out that study participants
could develop asymptomatic CAD over the course of the
study but this is unlikely given the limited duration.
This study was not placebo controlled because it was
not sponsored by pharmaceutical companies and no pla-
cebo medication could be provided. Instead, patients re-
ceived only background therapy during a control period,
which was then compared to liraglutide treatment.
The size of the study population was small in this pilot
study. The sample size of the study was determined by
power calculations and the number of patients reduced
by using the cross-over design. Calculations were based
on the assumption that an improvement in CFR of 0.3
was clinically relevant. We found a difference in CFR
between treatment allocations of 0.16 with a 95% CI of
[-0.08; 0.40]. An improvement of 0.16 or more may be
clinically relevant if confirmed in larger trials.
Finally, it is possible that the two weeks wash-out
period was insufficient to avoid cardiovascular effects of
liraglutide to be referred. However, this limitation was
addressed by calculating carry over effect which was
non-significant for the primary outcome CFR.
Conclusion
Despite a significant weight-loss, reduction in HbA1c and
systolic blood pressure, we found only a small and non-
significant improvement in CFR after 10 weeks treatment
with liraglutide. In our short-term treatment study, we
therefore conclude that the GLP-1 analogue liraglutide
does not have any significant effect on coronary microcir-
culation in patients with type 2 diabetes. We also conclude
that liraglutide has no effect on peripheral endothelial
function in patients with type 2 diabetes. This study con-
tributes to the highly important clinical issue of improving
cardiovascular risk profile in patients with type 2 diabetes.
Further long-term studies, preferably in patients with more
impaired microvascular function and using a higher dosage
of GLP-1 analogues, are needed to confirm these findings.
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Additional file 1: Carry over, period and sequence effect for primary
and secondary outcomes after performing analysis of variance
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over, period and sequence effect. ANOVA-analysis for cross-over design
experiments were used (pkcross command in STATA 13.1). Abbreviations:
CFR coronary flow reserve, RHI reactive hyperaemia index, AI augmentation
index, HbA1c glycated haemoglobin, BP blood pressure, HOMA Homeostatic
Model Assessment.
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